Actively Recruiting
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Led by Sun Yat-sen University · Updated on 2025-12-11
192
Participants Needed
1
Research Sites
144 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
CONDITIONS
Official Title
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understands and voluntarily signs the informed consent form.
- ECOG performance status of 0 or 1.
- Expected survival longer than 3 months.
- Histologically or cytologically confirmed advanced invasive breast cancer.
- Histological type must be HR+/HER2- or HR-/HER2- as defined by specific hormone receptor and HER2 criteria.
- Previous failure of first-line treatment for metastatic disease, including endocrine therapy with CDK4/6 inhibitors for HR+/HER2- or chemotherapy with PD-1 inhibitors or PARP inhibitors for TNBC as applicable.
- At least one measurable lesion according to RECIST criteria.
- Adequate organ function including bone marrow, kidney, liver, and heart.
- Premenopausal women must use medically acceptable contraception during the study.
- Compliance with the study protocol.
You will not qualify if you...
- Investigator judgment that medical conditions like uncontrolled hypertension or active infection would interfere with study participation or compliance.
- Persistent toxicities from previous anti-tumor treatments not improved to Grade 2 or baseline.
- Presence of neoplastic spinal cord compression or active brain metastases.
- Significant fluid retention such as ascites or pleural effusion.
- Uncontrolled infection requiring intravenous antibiotics.
- Active or uncontrolled hepatitis B or C infection.
- Uncontrolled or significant heart disease.
- Suspected interstitial lung disease or non-infectious pneumonia.
- Active autoimmune or inflammatory diseases, including inflammatory bowel disease.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
Z
Zhong-yu Yuan, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here